Trastuzumab Plus Tamoxifen: Anti-Proliferative and Molecular Interactions in Breast Carcinoma

By Ropero Santiago   Abel Menéndez Javier   Vázquez-Martín Alejandro   Montero Sagrario   Cortés-Funes Hernán   Colomer Ramon  

Breast Cancer Research and Treatment, Vol. 86, Iss. 2, 2004-07 ,pp. : 125-137

Springer Publishing Company

Access to resources Recommend Favorite

Anti-tumor immunity induced by an anti-idiotype antibody mimicking human Her-2/neu

By Mohanty Kartik   Saha Asim   Pal Smarajit   Mallick Palash   Chatterjee Sunil   Foon Kenneth   Bhattacharya-Chatterjee Malaya  

Breast Cancer Research and Treatment, Vol. 104, Iss. 1, 2007-07 ,pp. : 1-11

Springer Publishing Company

Access to resources Recommend Favorite

Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023

By Kerklaan Bojana   Diéras Veronique   Tourneau Christophe   Mergui-Roelvink Marja   Huitema Alwin   Rosing Hilde   Beijnen Jos   Marreaud Sandrine   Govaerts Anne-Sophie   Piccart-Gebhart Martine   Schellens Jan   Awada Ahmad  

Cancer Chemotherapy and Pharmacology, Vol. 71, Iss. 1, 2013-01 ,pp. : 53-62

Springer Publishing Company

Access to resources Recommend Favorite

Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model

By        

Oncology Reports, Vol. 30, Iss. 3, 2013-01 ,pp. : 1087-1093

Spandidos Publications

Access to resources Recommend Favorite

Bispecific antiCD3 x antiHER2 antibody mediates T cell cytolytic activity to HER2positive colorectal cancer in vitro and in vivo

By  

International Journal of Oncology, Vol. 45, Iss. 6, 2014-01 ,pp. : 2446-2454

Spandidos Publications

Access to resources Recommend Favorite